Gross Profit Analysis: Comparing Exelixis, Inc. and Halozyme Therapeutics, Inc.

Biotech Giants: Exelixis vs. Halozyme Profit Growth

__timestampExelixis, Inc.Halozyme Therapeutics, Inc.
Wednesday, January 1, 20142306800052602000
Thursday, January 1, 201533277000105812000
Friday, January 1, 2016184902000113485000
Sunday, January 1, 2017437411000285461000
Monday, January 1, 2018827478000141726000
Tuesday, January 1, 2019934678000150446000
Wednesday, January 1, 2020951266000224227000
Friday, January 1, 20211382097000361897000
Saturday, January 1, 20221553153000520812000
Sunday, January 1, 20231757661000636892000
Monday, January 1, 20242168701000855907000
Loading chart...

Data in motion

Gross Profit Growth: Exelixis vs. Halozyme

In the dynamic world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, Exelixis, Inc. and Halozyme Therapeutics, Inc. have shown remarkable growth in their gross profits. Starting in 2014, Exelixis reported a modest gross profit, but by 2023, it had skyrocketed by over 7,500%, reaching its peak. This impressive growth reflects Exelixis's strategic advancements and market positioning.

Conversely, Halozyme Therapeutics, while also experiencing growth, saw a more moderate increase of approximately 1,100% over the same period. This steady rise highlights Halozyme's consistent performance and resilience in the competitive biotech sector.

The data underscores the contrasting growth trajectories of these two companies, offering valuable insights for investors and industry analysts. As the biotech landscape continues to evolve, monitoring such financial trends becomes crucial for making informed decisions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025